Results 311 to 320 of about 129,283 (392)

Are single nucleotide polymorphisms underutilized for guiding treatment of inflammatory bowel disease?

Immunology &Cell Biology, EarlyView.
Patients with inflammatory bowel disease (IBD) show variation in their response to therapeutics. This review explores the contrast between heritable single nucleotide polymorphisms (SNPs) that contribute the pathogenesis of IBD, versus those that associate with response to treatments.
Jildou van der Werf, Nicholas Ian Fleming   +1 more
wiley   +1 more source

Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions. [PDF]

J Clin Med
Khan MA, Hanna A, Sridhara S, Chaudhari H, Me HM, Attieh RM, Abu Jawdeh BG.   +6 more
europepmc   +1 more source

Connective tissue disease‐associated interstitial lung disease: an approach to treatment amidst an expanding evidence base

Internal Medicine Journal, EarlyView.
ABSTRACT Connective tissue disease‐associated interstitial lung disease (CTD‐ILD) comprises a heterogenous group of conditions characterised by immune‐mediated fibro‐inflammatory pulmonary injury. Although the disease course is variable, CTD‐ILD can progress to respiratory failure and thus has a profound impact on morbidity and mortality.
Michael Hong, Elizabeth Veitch, Sandhya Limaye   +2 more
wiley   +1 more source

Lung involvement is a risk factor for treatment resistance in patients with polymyositis and dermatomyositis. [PDF]

Arch Rheumatol
Altunel Kılınç E, Duman BE, Özbek S.
europepmc   +1 more source

Forty years of experience with liver transplantation [PDF]

, 1997
Starzl, TE
core  

Perineural Spread of Orbital Immunoglobulin G4-Related Disease: A Case Report. [PDF]

Cureus
Sirvisetty H, Bockhorst S, Hamidi R.
europepmc   +1 more source

Milestones in Transplantation: The Story so Far [PDF]

, 2001
Starzl, TE
core  

European Guideline (EuroGuiDerm) on atopic eczema: Living update

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, S. Barbarot, T. Bieber, H. A. Brough, P. Calzavara‐Pinton, S. Christen‐Zaech, M. Deleuran, M. Dittmann, N. Fosse, K. Gáspár, L. A. A. Gerbens, U. Gieler, G. Girolomoni, S. Gregoriou, S. Holland, C. G. Mortz, A. Nast, U. Nygaard, E. M. Rehbinder, J. Ring, M. Rossi, E. Serra‐Baldrich, D. Simon, Z. Z. Szalai, J. C. Szepietowski, A. Torrelo, T. Werfel, R. N. Werner, C. Flohr   +31 more
wiley   +1 more source

Review of: Hill RB, Rowlands DT, Rifkind D: Infectious pulmonary disease in patients receiving immunosuppressive therapy for organ transplantation [PDF]

, 1999
Starzl, TE
core  

Clinical Images: Flail elbows: destructive calcium pyrophosphate crystal arthritis. [PDF]

ACR Open Rheumatol
Szlembarski S, Falaas K, Gertner E.
europepmc   +1 more source